2 results
Approved WMOPending
The aims are: (1) to explore the feasibility of XRNT treatment in the Netherlands in terms of treatment participation and treatment retention; and (2) to study the mechanism of action of XRNT using pharmacoMRI and SPECT, and (3) to study the…
Approved WMORecruiting
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…